Recommendation ID
Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?
Any explanatory notes
(if applicable)
It has been estimated that 8000 to 10,000 MS relapses will occur each year in the UK, which place a burden on individual patients and the NHS. The primary treatment of acute relapses is with corticosteroids, using a variety of different dosing regimens with both intravenous and oral administration. There is large variation in practice around the UK. The available evidence does not directly compare equivalent doses of oral and intravenous methylprednisolone in the subacute setting in which it is usually delivered.

Source guidance details

Comes from guidance
Multiple sclerosis in adults: management
Date issued
October 2014

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 27/11/2014